Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Octreotide and chylothorax.

Ioannis Kalomenidis1

  • 1Department of Critical Care and Pulmonary Services, Athens Medical School, Evangelismos Hospital, Athens, Greece. jkalomenidis@hotmail.com

Current Opinion in Pulmonary Medicine
|July 11, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prognostic Value of Lung Injury Biomarkers in Patients Hospitalized With COVID-19 Without Respiratory Failure at Admission.

Critical care medicine·2026
Same author

Remdesivir: Real-World Effectiveness and Safety in Individuals Hospitalized for Non-COVID Reasons and Non-Hospitalized High-Risk Patients During the Omicron Era in Greece.

Microorganisms·2026
Same author

Effects of Apnoea versus Normal Breathing on Physiological Responses during High-Intensity Interval Training in Swimming.

Journal of human kinetics·2025
Same author

Remdesivir: Effectiveness and Safety in Hospitalized COVID-19 Patients-Analysis of Retrospectively Collected Data from Daily Practice in the Omicron Variant Era and Comparison with the Pre-Omicron Period.

Microorganisms·2025
Same author

Blood immunomap for prediction of responses to anti-PD-1 immunotherapy in metastatic non-small cell lung cancer.

iScience·2025
Same author

29-mRNA host response signatures for classification of bacterial infection, viral infection and disease progression in COVID-19 pneumonia: a post hoc analysis of the SAVE-MORE randomized clinical trial.

Intensive care medicine experimental·2025
Same journal

Nonsteroid treatment options in (pulmonary) sarcoidosis. When to consider and why?

Current opinion in pulmonary medicine·2026
Same journal

Multidisciplinary approach in cardiac sarcoidosis: to biopsy or not?

Current opinion in pulmonary medicine·2026
Same journal

Low diffusion capacity in pulmonary hypertension.

Current opinion in pulmonary medicine·2026
Same journal

Toward precision imaging in interstitial lung disease: advances in quantitative imaging and artificial intelligence.

Current opinion in pulmonary medicine·2026
Same journal

Oxygen therapy in interstitial lung disease - navigating benefit and burden.

Current opinion in pulmonary medicine·2026
Same journal

Preclinical and clinical advances in pulmonary hypertension associated with systemic sclerosis.

Current opinion in pulmonary medicine·2026
See all related articles

Octreotide, a synthetic somatostatin analogue, shows promise in treating chylothorax by reducing lymph flow. Further randomized controlled trials are needed to confirm its efficacy and safety for this condition.

Area of Science:

  • Medical Science
  • Pharmacology
  • Thoracic Surgery

Background:

  • Chylothorax is a condition characterized by the accumulation of lymphatic fluid in the pleural cavity.
  • Current management involves chest tube drainage and dietary modifications, with surgery as a last resort.

Purpose of the Study:

  • To review the existing literature on the use of somatostatin and octreotide for chylothorax treatment.
  • To evaluate the safety and potential effectiveness of octreotide in managing chylothorax.

Main Methods:

  • Literature review of case reports and series concerning octreotide treatment for chylothorax.
  • Analysis of reported outcomes, including lymph flow reduction and treatment duration.

Main Results:

Related Experiment Videos

  • Octreotide appears safe and potentially effective for chylothorax in pediatric and adult patients.
  • A significant decrease in chest tube lymph drainage is often observed within days of initiating octreotide therapy.
  • Treatment duration typically ranges from 1 to 2 weeks, though treatment failures have been documented.

    • Conclusions:

    • Octreotide represents a potential novel therapeutic option for chylothorax.
    • High-quality randomized controlled studies are essential to establish the definitive efficacy and safety profile of octreotide.